



Smart device sold separately.*

Dexcom G7 – **covered by RAMQ** for more patients living with diabetes on intensive insulin therapy.*

Effective November 6, 2025.

Prescribe the #1 preferred CGM by Canadian endocrinologists.^{†,1}

NEW DEXCOM G7 or G6 sensors **RAMQ CRITERIA:**

≥ 18 yo T1 or T2 on intensive insulin therapy*

PLUS ANY 1 OF THE FOLLOWING:



A1C not at target



Frequent hypoglycemia episodes



Hypoglycemia unawareness

Dexcom G7 is the only CGM with **unique alerts** which support insulin therapy and improved glycemic outcomes.^{2,3}

- **Predictive Urgent Low Soon alert[‡]** warns of severe hypoglycemia up to 20 minutes before it happens.⁴
- **Delayed 1st high alert** encourages action for sustained high glucose – get back in range after meals.^{4,5}

Start your patients on Dexcom G7 today through RAMQ portal and a prescription.

FREE Optional Dexcom G7 receivers for patients are available by calling: **1-844-832-1810.**



JOIN OUR LIVE 30-MIN WEBINAR FOR MORE INFORMATION!

T1 = Type 1 Diabetes | T2 = Type 2 Diabetes | yo = years old | CGM = Continuous Glucose Monitor
*For patients with type 1 (2 years and older) or type 2 (18 years and older) on intensive insulin therapy (treatment by insulin pumps or ≥ 3 insulin injections per day) and meets RAMQ eligibility criteria. Visit dexcom.com/coverage for more information. †Based on a survey of Canadian endocrinologists (n=41). ‡Smart device sold separately. For a list of compatible devices, visit dexcom.com/compatibility. 1 dQ&A, Dexcom Canadian Endos Report Wave 1 2024. 2 Pühr S, et al. DTT. 2019;21(4):155-8. 3 Aly A, et al. DTT. 2024;26(S2): A254-2558. 4 Dexcom G7 User Guide. 5 Dexcom, Data on File, 2025. Dexcom and Dexcom G7 are registered trademarks of Dexcom, Inc. in the US and may be registered in other countries. © 2025 Dexcom Canada, Co. All rights reserved. MAT-10539 V1.0

dexcom G7
ALWAYS A STEP AHEAD